Integrated Review of Security, Defence, Development and Foreign Policy

Sarah Champion Excerpts

Tuesday 9th February 2021 Commons Chamber

[Sarah Champion (Rotherham) (Lab) [V]]

It is almost a year since the Prime Minister launched his integrated review into the UK’s international policy, and how the world has changed since then. The review is supposed to map out how the levers of our diplomatic, development and defence policy work together, providing a truly integrated international strategy for the decades ahead, but despite assurances that it would be published last autumn there is still no sign of it. We have, however, seen a drip of premature announcements linked to the review about increases to defence spending, reductions to development spending, and of course the merger between DFID and the FCO last summer.

To make such a momentous decision as a merger before completing the review denied many external stakeholders the opportunity to contribute evidence, and pre-empted the review’s conclusions. It was a deep mistake and will have long-term consequences. By cutting UK aid spending to 0.5% of gross national income from 2021 onwards, the Government have broken their promise that the integrated review would be underpinned by an ongoing commitment to spend 0.7% of UK GNI on official development assistance. Reducing our spending at a time of increased global need while our allies in France and Germany seek to increase their development spend sends a message of a country backing away from solving problems and sharing burdens, rather than taking the lead in finding solutions.

In normal times, we would be talking about how to ensure that our aid budget is reaching the people most in need of it, whether it is delivering value for money, and whether it is sufficiently transparent. We need to get back to those conversations. I am pleased that the Government plan to publish a new development strategy, born out of the conclusions and objectives that will be set out in the integrated review. That new strategy will provide an opportunity for the UK to cement its commitment to poverty reduction and the attainment of the sustainable development goals. The International Development Committee, which I chair, is keen to contribute to that new strategy, ensuring that it draws upon the views of stakeholders from across the world.

When the Foreign Secretary spoke to my Committee last month, he told us of his vision for the UK to be an international leader in conflict and dispute resolution. To undertake that role with credibility we must first remove the contradictions that persist in our international policy. How can the UK take the global lead in tackling climate change but continue to support the use of fossil fuels through UK Export Finance? How can we share our commitment to providing quality education for girls when one of the first casualties of aid cuts was a girls’ education programme in Rwanda? How does it make sense for the UK to be rightly providing humanitarian assistance to Yemen yet continuing to sell arms to the countries that use those weapons on the Yemeni people?

The integrated review is our chance to tell the world what sort of country the UK wants to be. I want it to be one that promotes peace, equality and prosperity for all, so I have to ask: when will the integrated review be published?

Yemen

Sarah Champion Excerpts

Monday 8th February 2021 Commons Chamber

[James Cleverly]

My hon. Friend makes a very important point about the UK’s contribution in Yemen. As I have said, we have contributed £1 billion since the conflict started. He will know that the official development assistance budget will be constrained because of the economic situation brought about by coronavirus. He also made the very important point that cash is not the only way that the UK is supporting people in Yemen. We have worked with our international partners to try to pursue peace. He also mentioned vaccinations in response to the coronavirus. I am very proud of the leading role that the United Kingdom took in working with international partners to raise funds to roll out vaccinations to those countries that were unable to do so, and I have no doubt that the UK will continue to be a leading player in the equitable and global distribution of vaccinations, as they are manufactured.

[Sarah Champion (Rotherham) (Lab) [V]]

For too long, Yemen has been the worst humanitarian crisis in the world, so what steps is the Minister taking to protect UK aid spending to Yemen from his Government’s cuts, and how is he encouraging the participation of women and girls in conflict resolution and peacekeeping in Yemen?

[James Cleverly]

I thank the hon. Lady for the points that she has made. As she knows, coronavirus has, in the UK and around the rest of the world, had severe and detrimental effect on our economies, and this will have an impact on our aid spend. Nevertheless, Yemen will remain a UK priority country, and we will continue to use the full force of our diplomatic efforts to bring about peace. I am also glad that she raised the importance of women peacebuilders. I myself have spoken—virtually, unfortunately—with women in Yemen. I am the ministerial lead for women, peace and security, and I have on numerous occasions called for the voices of women in Yemen and further afield to be right at the heart of decision making about peacebuilding. I will continue to do so.

UN International Day of Education

Sarah Champion Excerpts

Thursday 28th January 2021 Commons Chamber

[Sarah Champion (Rotherham) (Lab) [V]]

Today I will focus on the sustainable development goals, specifically SDG 4 on global education and SDG 5 on gender equality.

Even before the pandemic, 258 million children were out of school, including one in two children with disabilities, more than half of school-age refugee children and 75 million children whose education was disrupted by humanitarian crises. Covid-19 has obviously made everything so much worse. This week, the International Development Committee released a report on the secondary impacts of covid-19, highlighting a global education crisis. With schools shut down and teaching disrupted, decades of progress are at risk. Some 1.6 billion children and young people are suffering educational disruption and are unable to access their basic rights. Over 460 million children are unable to access remote learning while out of school. In addition, as livelihoods are lost, informal economies shrink and remittances from abroad plummet, struggling families are left unable to pay the school fees required in many schools. Unsurprisingly, all this impacts most on the children who are already marginalised: refugees, the internally displaced, children with disabilities, and girls.

This is a gendered crisis. Girls of secondary school age are far less likely to return than boys when the schools reopen. That is already against the backdrop of young women accounting for 59% of the total illiterate youth population. Online and remote learning is insufficient to reach all children during lockdown, as many do not have internet access or mobiles. Covid-19 has heightened economic pressure on family finances, with children forced into child marriage and child labour to help support their families. It increases violence and sexual exploitation, leaving children, particularly girls, to drop out of school permanently—and there are strong links between girls leaving education and subsequent increases in trafficking and exploitation.

With both the presidency of the G7 and the Global Partnership for Education, the Government have two major opportunities to galvanise action and remedy stalled progress towards SDGs 4 and 5. The Government made strong educational pledges before the cuts were announced. I ask the Minister: do those pledges still stand? The UK has still not pledged a penny to the Global Partnership for Education. The Government must pledge big and pledge now. The UK spends a paltry 5.6% of aid on education, and in 2018 just 0.3% was spent on ending violence against women and girls. I commend the Government’s intent on girls’ education, but their aim can only be achieved by increasing gender equality and real financial investment.

Foreign, Commonwealth and Development Office

Sarah Champion Excerpts

Monday 25th January 2021 Ministerial Corrections

The following are extracts from Foreign, Commonwealth and Development Office Question Time on Tuesday 19 January 2021.

[Sarah Champion (Rotherham) (Lab) [V]]

The Minister is right that vaccines alone are not enough, and she is aware that the International Development Committee has just done an inquiry on the secondary impacts, which show that developing countries are suffering economically through their healthcare and through gender inequality. What efforts and preparations are being made by FCDO to prevent there being a development mountain to climb after the pandemic subsides?

[Wendy Morton]

I recognise the work of the IDC and I am very pleased that its work is continuing. Let me just reiterate that when it comes to covid-19, the UK and the FCDO remain at the forefront. With the funds that we have, we continue to support the world’s poorest, and we will continue to focus on the bottom billion. Yes, it is about working with the development world, but it is also about working, where we can, with the public sector and the private sector. I look to the example of Oxford-AstraZeneca. The UK Government invested £84 million in helping to develop that vaccine, and we are now rolling it out. We have committed to the AMC, and we are absolutely committed to helping the world’s poorest.

[Official Report, 19 January 2021, Vol. 687, c. 761.]

Letter of correction from the Under-Secretary of State for Foreign, Commonwealth and Development Affairs, the hon. Member for Aldridge-Brownhills (Wendy Morton):

An error has been identified in the response I gave to the hon. Member for Rotherham (Sarah Champion).

The correct response should have been:

Oral Answers to Questions

Sarah Champion Excerpts

Tuesday 19th January 2021 Commons Chamber

[Wendy Morton]

I do not accept the hon. Lady’s assertions when it comes to transparency. We, the UK, are absolutely at the forefront of multilateral efforts on ensuring equitable global access. If we look at what the UK Government have done, we see that we have contributed to CEPI—the Coalition for Epidemic Preparedness Innovations—in the early part of this pandemic and to FIND, the Foundation for Innovative New Diagnostics. We have contributed to Gavi and to the COVAX AMC. This is all about helping the world’s poorest. We have also flexed a lot of our normal aid work to help countries that are suffering from the pandemic, because we know that, as well as the primary impact of covid-19, there are many secondary impacts.

[Sarah Champion (Rotherham) (Lab) [V]]

The Minister is right that vaccines alone are not enough, and she is aware that the International Development Committee has just done an inquiry on the secondary impacts, which show that developing countries are suffering economically through their healthcare and through gender inequality. What efforts and preparations are being made by FCDO to prevent there being a development mountain to climb after the pandemic subsides?

[Wendy Morton]

I recognise the work of the IDC and I am very pleased that its work is continuing. Let me just reiterate that when it comes to covid-19, the UK and the FCDO remain at the forefront. With the funds that we have, we continue to support the world’s poorest, and we will continue to focus on the bottom billion. Yes, it is about working with the development world, but it is also about working, where we can, with the public sector and the private sector. I look to the example of Oxford-AstraZeneca. The UK Government invested £84 million in helping to develop that vaccine, and we are now rolling it out. We have committed to the AMC, and we are absolutely committed to helping the world’s poorest.[Official Report, 25 January 2021, Vol. 688, c. 2MC.]

Hong Kong: Sentencing of Pro-democracy Activists

Sarah Champion Excerpts

Monday 7th December 2020 Commons Chamber

[Madam Deputy Speaker (Dame Rosie Winterton)]

Order. Not too many conversations across the Chamber, please. We need to move on fairly promptly to the next piece of business, because a lot of speakers wish to contribute to that, so before we go to Sarah Champion, I make a brief plea for concise questions and answers.

[Sarah Champion (Rotherham) (Lab) [V]]

Pro-democracy campaigner and owner of Apple Daily newspaper, Jimmy Lai, is a British citizen, so can the Minister confirm that he is receiving consular assistance? Does he believe that denying a 73-year-old man bail is proportionate or fair for allegedly breaking the terms of a lease? What conversations is he having with Carrie Lam about the use of the law in this manner?

[Nigel Adams]

We regularly raise our concerns directly with the Hong Kong authorities in this regard. We are very concerned about the arrest of Jimmy Lai and others. Normally, we do not provide consular assistance to dual nationals in the country of their other nationality. China does not recognise dual nationality. It is therefore impossible to be granted permission to provide consular assistance.

Official Development Assistance

Sarah Champion Excerpts

Thursday 26th November 2020 Commons Chamber

[Dominic Raab]

I thank my hon. Friend. He will be able to work out that the difference is £4 billion in savings next year. Of course we looked at whether we could just follow the contraction in GNI to deliver the savings that we need. We looked at every single option, but the challenge we have is that the pandemic is uncertain. That is what we found in the throes of coming out of the second national lockdown. As a result, the impact on the economy and the public finances is not just profound but also uncertain.

My hon. Friend asked some further questions about our seriousness in getting back to 0.7%. We are serious. He is right to say that it was a manifesto commitment that we were proud of, but I think that the country expects us to stand up and make difficult decisions, given the necessity of the situation that we face. We have made it clear that it is temporary, and we will get back to it just as soon as the public finances allow.

[Sarah Champion (Rotherham) (Lab) [V]]

In the past six months, the Foreign Secretary has closed DFID, tried to abolish the Select Committee on International Development and cut more than a third of the aid budget. We still have no clarity on where those cuts have been or will be made, or their consequences. I have specific concerns about some of the areas that he details as priorities, as they might fall outside the ODA definition. The science element is written to fit the heavily criticised Newton Fund, and the trade aspect could lead to tied aid. In his letter to me, he states that

“too often, aid has lacked coherence, oversight or appropriate accountability across Whitehall.”

The same could be said in relation to Parliament. To address that, will he agree to present to the House an impact assessment of the cuts? Will he also agree to support the International Development Committee’s change of remit, so that we can scrutinise all ODA, so that both taxpayers and Members of Parliament may be assured that the money is being well spent?

[Dominic Raab]

I have to say to the hon. Lady, whom I respect and admire greatly, that we have not closed DFID, but merged the Foreign Office and DFID, precisely to give greater impact given the financial pressures we now face. She asked about tied aid; we are not suggesting any reversion to tied aid, which comes from a bygone era and is not something that I or this Government support. Nor have we tried to abolish the Select Committee; I have made it clear every time I have been asked, such matters are for the House to decide. Finally, she asked about when we will publish the GNI review detailed breakdown. Obviously, we are committed to full transparency, and the statistics on international development are published next year. They will be provided through a detailed breakdown of all the ODA allocations in 2020.

Oral Answers to Questions

Sarah Champion Excerpts

Tuesday 24th November 2020 Commons Chamber

[Wendy Morton]

My right hon. Friend makes a really important point. I know of his continued interest in education, particularly girls’ education. I assure him that we have established regular senior engagement with the Global Partnership for Education and our Kenyan co-hosts to ensure a successful replenishment that delivers major funding for girls’ education. We will secure significant pledges through bilateral engagement and in global forums from both traditional donors and new partners, and through domestic and global networks we will build attention to and expectation around this important replenishment.

[Sarah Champion (Rotherham) (Lab) [V]]

The Minister is aware that girls can only benefit from education if we tackle child marriage, female genital mutilation and all gender-based violence. NGOs report that funding for GBV programmes are not keeping up with the rise in cases due to covid-19. In October, the United Nations Population Fund stated that

“funding for GBV prevention and response remains unacceptably low.”

Is the UK going to further increase UK official development assistance for GBV programmes to combat the secondary impacts of covid-19 on women and girls? Is the money ring-fenced? And will the Minister be challenging the Chancellor’s attack on foreign aid, which will undermine all this work?

[Wendy Morton]

The hon. Lady may attempt to draw me into the debate on aid, but she knows that I am not going to speculate on that. She emphasises the importance of girls’ education. The UK is a world leader in our education expertise and our development spend. As I said, since 2015—[Interruption.] Opposition Front Benchers may mutter, but let us be absolutely clear: the UK has supported 15.6 million children to gain a decent education, and 8 million of those are girls. Our country direct programme for research and funding to organisations such as the Global Partnership for Education and Education Cannot Wait makes the UK a global leader in promoting girls’ education.

Hong Kong

Sarah Champion Excerpts

Thursday 12th November 2020 Commons Chamber

[Nigel Adams]

I can confirm that the Chinese ambassador has been summoned to the Foreign Office this morning. Freedom of religion or belief is a key issue for this Government. My hon. Friend has spoken on this matter on many occasions, and I have had the pleasure to be in such debates. We are very concerned by what has been going on in mainland China—particularly in Xinjiang—but we are concerned by all restrictions placed on freedom of religion or belief in China.

[Sarah Champion (Rotherham) (Lab) [V]]

It started with the disappearance of a bookseller. Then there was state-sanctioned violence against protesters and health workers, university lecturers were sacked and the free press challenged. Twelve Hong Kong youths have been detained for over 80 days, and now we see the disqualification of four moderate legislators. Things are clearly escalating. What will the Minister actually do to hold China to account for the breach of the joint declaration and international treaties, and what consular support is he providing to Hongkongers?

[Nigel Adams]

As I have laid out in previous answers, we are working with international partners and have summoned the Chinese ambassador. We have done an immense amount of work at the United Nations whenever we believe that China is transgressing, particularly on human rights. We could not be any clearer; our assessment is that this action is a breach of the joint declaration. This is a subject on which we have been incredibly robust over the past 12 months, as the hon. Lady will know. The joint declaration is in force and the policies contained within it should remain unchanged for 50 years. It is a legally binding international agreement that is registered with the UN, and we are fully committed to upholding Hong Kong’s high degree of autonomy, rights and freedoms.

International Covid-19 Response: Innovation and Access to Treatment

Sarah Champion Excerpts

Thursday 5th November 2020 Commons Chamber

[Sarah Champion (Rotherham) (Lab)]

I thank the hon. Member for North East Fife (Wendy Chamberlain) for calling for the debate, and I hope that my speech will amplify the points that she is making.

The International Development Committee, which I chair, has been examining the impact of the coronavirus on developing countries, and the contribution of the UK Government to initiatives to help the global south tackle the pandemic. A key part of the UK’s strategy for the global south is funding an array of partnerships and collaborations aiming to develop, at speed, vaccines, therapies and tests for preventing, treating and diagnosing the disease. The Government have allocated the lion’s share of their global coronavirus funding to the race for those products—£388 million initially for vaccines, therapies and tests and, more recently, another £571 million for the production, purchase and distribution of vaccines. That is very welcome, but a key concern that emerged throughout the evidence that we received was about the importance of legal and practical measures to guarantee equitable access to corona vaccines, medicines and tests around the world, based on need, not economic power. The former chief scientific adviser to the Department for International Development, Professor Charlotte Watts, told the IDC:

“It is not only about finding a vaccine that is going to work, but how to ensure that there are the resources and future investment in production capability, so that that can be distributed to low and middle-income countries.”

It is worth recalling why equitable access to medicines is such a concern. First, let me take the example of the antiretrovirals for HIV and AIDS. In Durban in 2000, at the XIII International AIDS Conference, Justice Edwin Cameron of the South African Constitutional Court famously declared that he had been living with AIDS for 33 months, but that,

“there are 24 or 25 million people in Africa who at this moment are dying, and they are dying because they don’t have the privilege that I have of purchasing my life and health.”

In 2000, the anti-retroviral drugs capable of transforming AIDS into a manageable illness were far beyond the means of most South Africans, costing up to $10,000 a year—much more expensive than any other country when compared with generic substitutes. When South Africa passed legislation to facilitate the use of cheaper, generic and imported products on public health grounds, 39 multinational pharmaceutical companies banded together to sue the Government for violating WTO rules. Rightly, that resulted in a PR disaster for the pharmaceutical industry. The case was dropped and the WTO recognised member states’ rights to take such measures to protect public health and, in particular, to promote access to medicines for all. But even now, the use of that safeguard is largely limited to the original HIV/AIDS drugs because of the complexities required in legislation, health system weaknesses and political pressure.

Let us look at cancer. Cancer drugs are a lucrative pharmaceutical market—for example, representing 27% of the sector’s revenue in the US. Efforts to set prices to recoup research and development costs over a set period are one thing, but funding the inflated billion-dollar trade in whole companies holding just one or two attractive patents seems less defensible. Whatever the reason, low and middle-income countries invariably find the prices set to take advantage of demand in a high-income country an insurmountable barrier to access. Pricing invariably results in wide variations in survival rates. For example, the US five-year overall survival rate for breast cancer is 84%, compared with just 12% in Gambia. That is hardly equitable.

Finally, I want to talk about polio. The polio story is essentially a triumph, with a 99% reduction in cases since the start of the global effort in 1985. However, each year, the oral polio vaccine, which is widely used in the global south, is linked to outbreaks of the disease where the wild virus has been eliminated. The injectable vaccine is an inactive virus, but it costs about $3. The oral vaccine, at about 12 cents, contains live virus. Unfortunately, children can shed a mutated version of the live virus in their stools, which can then infect unvaccinated children in areas with poor sanitation. Clearly there are other considerations than just costs when comparing injected and ingested doses of medicine, but the reality is that cost kills.

Let us hold these examples in our mind as we consider equitable access to future coronavirus products. And let me be blunt: the prospect of the international community behaving morally, or at least rationally, on a global scale over the distribution of an effective vaccine, or even accurate and simple tests, at an affordable price, is not good. In his September speech to the first virtual United Nations General Assembly, the Prime Minister rightly lambasted the international community over its fractious and competitive reaction to the procurement of personal protective equipment during the first wave of the pandemic—and that was just over masks and aprons. Imagine the pressure on every Government to deliver the long-awaited panacea of covid-19 immunity to their own populations.

Any rational response to the pandemic must surely take account of the science and the almost unique status of this crisis by incorporating the sustainable development principle of leaving no one behind. No one will be safe and secure until everyone is covid-free. For once, everyone’s interests are overtly aligned. The UK finds itself in a unique moment in time when we can reposition ourselves as a global leader for good. The soft power gained by doing the right thing for the very poorest in the world, and by standing up to those looking to profit from others’ misery, will be immeasurable. I am grateful for the leading role the UK has taken to date in the development of covid vaccines and products.

[Patrick Grady]

I will be brief, because there is pressure on time, but I just want to say that the hon. Lady is making an incredibly powerful speech that is demonstrating the importance of the scrutiny that her Select Committee has been able to provide. I want to re-emphasise the point I made to the hon. Member for North East Fife (Wendy Chamberlain) that the Scottish National party fully supports the continuation of that Committee, either as a non-departmental Select Committee or as a wider official development assistance-scrutinising Committee. I hope that those on the Government Benches will bear that in mind.

[Sarah Champion]

I am extremely grateful for the hon. Member’s support of the International Development Committee. Development is a specific and key area of the work that we do, and it demands parliamentary scrutiny.

I ask the Minister to give us some certainty today on the Government’s commitment and resolve to fight to ensure that covid drugs and treatments are accessible to everybody, not just those with the deepest pockets. Will the Government support the proposed waiver of all intellectual property monopolies related to covid-19 tools, as put forward by India and South Africa to the WTO? Can the Minister confirm that, for all R&D projects that the UK has funded, transparency on finances and an obligation for resulting products to be free from monopolies were embedded in those contracts at the start and will be enforced? Finally, will the Government follow Germany, Australia, Canada and Israel in championing the use of legal safeguards that all World Trade Organisation members can implement to override patent monopolies if public health is at risk?

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Foreign, Commonwealth and Development Affairs (Wendy Morton)]

I thank all Members for contributing to the debate. In particular, I am grateful to the hon. Members for North East Fife (Wendy Chamberlain) and for Rotherham (Sarah Champion) for securing the debate. I also pay tribute to the hon. Member for Rotherham for her work on this issue in her role as Chair of the International Development Committee. As a former member of that Committee, once upon a time, I recognise the work that it has done over many years.

I am conscious that Members asked a number of specific questions of me on a number of themes. I will do my best to answer as many of them as I possibly can, but I shall also make some comments of my own.

Innovation and equitable access to treatments are critical in the fight to end the covid-19 pandemic. The UK is committed to ensuring rapid and equitable global access to safe, effective vaccines, therapeutics and diagnostics. On 26 September, the Prime Minister told the United Nations General Assembly that

“no one is safe until everyone is safe”—

a phrase that I have heard Members use in this Chamber on many occasions. It is that important that I am sure we will continue to use it.

The Prime Minister also told the UN General Assembly:

“The health of every country depends on the whole world having access to”

safe and effective vaccines, treatments and tests. The Government are working to deliver on that commitment through our innovation and scientific co-operation, our leading levels of funding and our close collaboration with other nations and multilateral partners. Scientific co-operation has led to swift breakthroughs and enhanced our collective knowledge of how to tackle this virus. The UK has played its part by supporting clinical trials of life-saving treatments and backing vaccine research at the University of Oxford and Imperial College London.

In June, the recovery trial based at the University of Oxford announced that dexamethasone, a low-cost corticosteroid, was the first treatment in the world shown to reduce the risk of mortality in hospitalised covid-19 patients who required oxygen or ventilation. Dexamethasone is a widely available and—crucially—affordable drug that is now being used to help covid-19 patients. This was the first robust clinical trial anywhere in the world to show a treatment that significantly reduces patient mortality for those with covid-19. Such a breakthrough was possible only thanks to our world-class British life sciences, and has been described by Dr Tedros, director-general of the World Health Organisation, as a “lifesaving scientific breakthrough.”

From the beginning of the pandemic, we have focused on robust clinical research. This enables us to take evidence-based decisions, backed by rigorous science, to improve access to effective treatments both in the UK and around the world. More broadly, the UK is committed to collaborating with public and private partners at home and abroad to accelerate development and equitable access in all countries to affordable health technologies to respond to covid-19. This includes exploring voluntary arrangements and approaches such as non-exclusive voluntary licensing that promote affordable access for all while also providing the incentives that help to foster the innovation needed to create new vaccines, treatments and tests.

The UK is proud to be the largest donor to the access to covid-19 tools, or ACT, accelerator. The ACT accelerator brings together leading international organisations in global health to support collaboration in developing and ensuring access to the new vaccines, treatments and diagnostics that will be needed to bring this pandemic under control.

[Sarah Champion]

Just out of curiosity, I am interested why we did not join ACT when it was initiated in April.

[Wendy Morton]

I will cover that point off later, if I may, but I make clear that we have made commitments to the ACT accelerator partners across the health technologies of up to £813 million. Our commitment is very clear. That includes up to £500 million to Gavi, the vaccine alliance, for the COVAX advance market commitment. The support will also help to ensure access to covid-19 vaccines for up to 92 low and middle-income countries, providing up to 500 million people with vaccinations. The UK is also the largest ACT accelerator donor to the Foundation for Innovative New Diagnostics, or FIND, which is leading the way in developing diagnostic tools for the world’s poorest countries.

In terms of treatments, the UK is providing up to £40 million to the covid-19 therapeutics accelerator, alongside the Bill and Melinda Gates Foundation, the Wellcome Trust, Mastercard and other funders. The covid-19 therapeutics accelerator and Unitaid lead the work of the ACT accelerator therapeutics partnership. Unitaid has a track record of helping companies to bring affordable health technologies to developing country markets quickly, and the UK is the second largest funder.

Our funding to the ACT accelerator is supporting a pipeline of promising treatments, including monoclonal antibodies and new antivirals. New clinical trial data will emerge in coming weeks. The ACT accelerator is also preparing the way for the rapid deployment of new therapeutics as soon as possible after they have proved effective. We have seen some impressive results so far, but we recognise that the scale of the crisis means more funding will be needed across all three health technologies. We will continue to work with our international partners to encourage them to join us in stepping up their support and to support new and innovative solutions to address this challenge.

The UK is proud to be at the forefront of international efforts to develop vaccines, treatments and tests and ensure equitable access for the world’s poorest countries, but we recognise that we cannot do that alone. Only through global collaboration with our international partners and working through effective multilateral systems will we bring the pandemic under control. That is why on 30 September, the Foreign Secretary co-hosted a side event at the UN General Assembly with the UN Secretary-General, the World Health Organisation director-general and the Health Minister of South Africa. The event raised up to $1 billion in bilateral contributions for the COVAX advance market commitment. The World Bank also announced a package of $12 billion of support for countries to access vaccines, treatments and tests, and a coalition of 16 industry leaders announced a shared commitment to equitable access, including not-for-profit pricing. The commitments by this range of partners are a powerful demonstration of the international support for the ACT accelerator and the need for partnership across the international system.

Vaccine nationalism was raised by Members on the Opposition Benches. In the UK, we are challenging vaccine nationalism. We are a leading supporter of the COVAX facility, which is open to all countries and aims to make vaccines widely available when they are proven. At the UN General Assembly, we used our diplomacy to convene countries in support of that and announced UK aid to fund the COVAX advance market commitment.

Intellectual property rights provide incentives to create and commercialise new inventions, such as life-changing vaccines. They keep innovators innovating, creators creating and investors investing. The UK believes that a robust and fair intellectual property system is a key part of the innovation framework that allows economies to grow while enabling society to benefit from knowledge and ideas. Multiple factors need to be considered to ensure equitable access for all to covid-19 vaccines. These include increasing manufacturing and distribution capacity, measures to support or incentivise technology transfer, ensuring that global supply chains remain open, and ensuring that effective platforms are utilised to voluntarily share IP and know-how.

The UK has long supported affordable and equitable access to essential medicines. We have not signed the solidarity call to action, but we remain committed to collaborating with public and private partners, including by exploring voluntary arrangements and approaches such as non-exclusive voluntary licensing.

[Wendy Morton]

I would just like to make a bit more progress so that I can cover as many points as possible.

Several hon. Member asked about the allocation of vaccines. I assure them that this is being considered. The World Health Organisation’s allocation framework recommends the highest priority populations by age, underlying conditions and health workers—estimated at about 3%. We cannot prevent a country from administering doses as they want, but there is a framework and countries will submit national deployment plans that will be reviewed by the WHO and COVAX.

The hon. Member for Strangford (Jim Shannon) raised the issue of inequalities for minority groups. I assure all hon. Members that we are working closely with organisations such as UNICEF and Gavi in that regard. These are organisations that we have worked with for many years.

I really hope that the House is reassured by the Government’s comprehensive approach to supporting innovation and equitable access to covid-19 vaccines, through scientific co-operation, working with industry, funding and multilateral collaboration. The UK is leading efforts to respond to the pandemic by developing and delivering the medical tools that are essential to ending the pandemic for everyone everywhere, but we must all work together to develop safe, effective and affordable vaccines, treatments and tests that can be produced quickly and made available to all.

[Sarah Champion]

I appreciate the Minister giving way. I just want to challenge her on the use of the word “voluntary” when it comes to intellectual property sharing and access to the vaccine. With all respect, big industry—particularly big pharmaceuticals—is not known for equitable sharing on a voluntary basis, so will the Minister please answer this specific point? When the UK taxpayer has been putting money into R&D, what right do we have to ensure that the information that we are paying for is shared in an equitable way?

[Wendy Morton]

As I explained, we believe that a robust and fair intellectual property system is a key part of an innovation framework that allows economies to grow while at the same time enabling society to benefit from knowledge and ideas. There are existing mechanisms that facilitate the sharing of IP—for example, expanding the mandate of existing organisations such as the Medicines Patent Pool to cover covid-19.

We have played a leading role, with our international and national partners, to identify end-to-end solutions that ensure affordable access for all, such as mechanisms to support the voluntary sharing of IP and know-how, manufacturing at scale and ensuring that no one is left behind, including the poorest and most vulnerable. We are committed to collaborating with public and private partners in the UK and internationally, including by exploring voluntary arrangements and approaches such as non-exclusive voluntary licensing, to help deliver what we all want, which is the promotion of affordable access while providing incentives to create those new innovations.

To conclude, it is fair to say that, if we are to defeat covid-19, and if we are to achieve a global recovery and avoid a future pandemic, we must work together across borders. Covid-19 is a virus that has no respect for borders or barriers, which is why the UK is promoting multilateral solutions to end the pandemic, working with international organisations, our partners in the G7 and G20 and industry.